ImmunoCellular Therapeutics, Ltd. - FORM 10-K - EX-23.2 - CONSENT OF STONEFIELD JOSEPHSON, INC. - March 21, 2012

Attached files

file filename
10-K - FORM 10-K - ImmunoCellular Therapeutics, Ltd.d283327d10k.htm
EX-10.51 - EXCLUSIVE LICENSE AGREEMENT - ImmunoCellular Therapeutics, Ltd.d283327dex1051.htm
EX-23.1 - CONSENT OF MARCUM LLP. - ImmunoCellular Therapeutics, Ltd.d283327dex231.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER UNDER SECTION 302 - ImmunoCellular Therapeutics, Ltd.d283327dex312.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER UNDER SECTION 302 - ImmunoCellular Therapeutics, Ltd.d283327dex311.htm
EX-32.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 - ImmunoCellular Therapeutics, Ltd.d283327dex321.htm
EX-32.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 - ImmunoCellular Therapeutics, Ltd.d283327dex322.htm
EXCEL - IDEA: XBRL DOCUMENT - ImmunoCellular Therapeutics, Ltd.Financial_Report.xls
EX-10.50 - PATENT LICENSE AGREEMENT - ImmunoCellular Therapeutics, Ltd.d283327dex1050.htm

Exhibit 23.2

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements of ImmunoCellular Therapeutics, Ltd. on Form S-8 (File Nos. 333-171652, 333-155199, 333-151968 and 333-147278) of our report dated March 29, 2010 with respect to our audit of the financial statements of ImmunoCellular Therapeutics, Ltd. as of December 31, 2009 and for the year ended December 31, 2009, and the period from February 25, 2004 (inception) to December 31, 2009, which report is included in this Annual Report on Form 10-K of ImmunoCellular Therapeutics, Ltd. for the year ended December 31, 2011.

/s/ Stonefield Josephson, Inc.

Los Angeles, California

March 21, 2012

ImmunoCellular Therapeutics, Ltd. Reports